JOM KITA KE POLITEKNIK

A new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry (Record no. 2071)

MARC details
042 ## - AUTHENTICATION CODE
Authentication code dc
100 10 - MAIN ENTRY--PERSONAL NAME
Personal name Björnsson, Einar S.
Relator term author
9 (RLIN) 1853
245 00 - TITLE STATEMENT
Title A new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. John Wiley and Sons Inc.,
Date of publication, distribution, etc. 2022-08-15.
500 ## - GENERAL NOTE
General note /pmc/articles/PMC7614006/
500 ## - GENERAL NOTE
General note /pubmed/35899490
520 ## - SUMMARY, ETC.
Summary, etc. BACKGROUND & AIMS: No multi‐national prospective study of drug‐induced liver injury (DILI) has originated in Europe. The design of a prospective European DILI registry, clinical features and short‐term outcomes of the cases and controls is reported. METHODS: Patients with suspected DILI were prospectively enrolled in the United Kingdom, Spain, Germany, Switzerland, Portugal and Iceland, 2016-2021. DILI cases or non‐DILI acute liver injury controls following causality assessment were enrolled. RESULTS: Of 446 adjudicated patients, 246 DILI patients and 100 had acute liver injury due to other aetiologies, mostly autoimmune hepatitis (n = 42) and viral hepatitis (n = 34). DILI patients (mean age 56 years), 57% women, 60% with jaundice and 3.6% had pre‐existing liver disease. DILI cases and non‐DILI acute liver injury controls had similar demographics, clinical features and outcomes. A single agent was implicated in 199 (81%) DILI cases. Amoxicillin‐clavulanate, flucloxacillin, atorvastatin, nivolumab/ipilimumab, infliximab and nitrofurantoin were the most commonly implicated drugs. Multiple conventional medications were implicated in 37 (15%) and 18 cases were caused by herbal and dietary supplements. The most common single causative drug classes were antibacterials (40%) and antineoplastic/immunomodulating agents (27%). Overall, 13 (5.3%) had drug‐induced autoimmune‐like hepatitis due to nitrofurantoin, methyldopa, infliximab, methylprednisolone and minocycline. Only six (2.4%) DILI patients died (50% had liver‐related death), and another six received liver transplantation. CONCLUSIONS: In this first multi‐national European prospective DILI Registry study, antibacterials were the most commonly implicated medications, whereas antineoplastic and immunomodulating agents accounted for higher proportion of DILI than previously described. This European initiative provides an important opportunity to advance the study on DILI.
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction © 2022 The Authors. Liver International published by John Wiley & Sons Ltd.
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
546 ## - LANGUAGE NOTE
Language note en
690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN)
Topical term or geographic name as entry element Metabolic & Toxic Liver Diseases
9 (RLIN) 1867
655 7# - INDEX TERM--GENRE/FORM
Genre/form data or focus term Text
Source of term local
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Stephens, Camilla
Relator term author
9 (RLIN) 1854
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Atallah, Edmond
Relator term author
9 (RLIN) 1855
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Robles‐Diaz, Mercedes
Relator term author
9 (RLIN) 1856
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Alvarez‐Alvarez, Ismael
Relator term author
9 (RLIN) 1857
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Gerbes, Alexander
Relator term author
9 (RLIN) 1858
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Weber, Sabine
Relator term author
9 (RLIN) 1859
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Stirnimann, Guido
Relator term author
9 (RLIN) 1860
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Kullak‐Ublick, Gerd
Relator term author
9 (RLIN) 1861
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Cortez‐Pinto, Helena
Relator term author
9 (RLIN) 1862
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Grove, Jane I.
Relator term author
9 (RLIN) 1863
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Lucena, M. Isabel
Relator term author
9 (RLIN) 1864
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Andrade, Raul J.
Relator term author
9 (RLIN) 1865
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Aithal, Guruprasad P.
Relator term author
9 (RLIN) 1866
786 0# - DATA SOURCE ENTRY
Note Liver Int
856 41 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://dx.doi.org/10.1111/liv.15378">http://dx.doi.org/10.1111/liv.15378</a>
Public note Connect to this object online.

No items available.